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1. SYNOPSIS 
 
Study Title: A prospective, observational, non-comparative, open-label study to investigate the effectiveness 
of the treatment with weekly Alendronate in postmenopausal women with Osteoporosis. 
 
Objectives: 
The primary objective of this study is to evaluate Bone Mineral Density (BMD) changes at lumbar spine of 
Greek osteoporotic women from baseline to 12th month from the initiation of Alendronate 70mg once 
weekly. 
The secondary objectives of this study are to estimate new vertebral and non-vertebral fragility fractures, hip 
fractures, treatment compliance, occurrence of back pain and days lost from work due to fracture related 
back pain from baseline to 12th month from the initiation of Alendronate 70mg once weekly. Also, to 
evaluate the safety of Alendronate assessed by the type, frequency, and severity of ADRs for 18 months after 
the initiation of study. 
 
Design and Outcomes: 
This is a Greek observational prospective study of 12 months to evaluate the effect of Alendronate 70mg 
once weekly on BMD change (%) at lumbar spine in postmenopausal women. The decision to treat the 
patient with Alendronate must be made independent of and prior to their enrollment in the study. Patients 
eligible to participate will receive their prescription monthly.  
Primary Outcome:  
- BMD change (%) at lumbar spine at 6,12 months of treatment measured by DXA 
Secondary Outcomes:  
- the proportion of patients with severe osteoporosis experiencing one or more new vertebral and 
non-vertebral fragility fractures assessed by spine radiographs regardless of symptoms 
- Compliance to therapy, self-reported by patients 
- Days lost from work due to fracture-related back pain, self reported by patients 
Secondary Safety Outcomes: 
- the proportion of patients with ADR to Alendronate 
- the proportion of patients with serious ADR to Alendronate 
 
Treatment Procedures and Duration: 
Patients will return to the clinic every month to receive their Alendronate 70mg prescription. Patients will be 
observed for a period of up to 12 months after their entry in the study and will be followed up for 6 months 
after their last visit.  
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Sample Size and Population: 
Inclusion criteria: Postmenopausal women who are diagnosed with osteoporosis. 
Exclusion criteria: Previous treatment with drugs that modify bone metabolism or serious 
bone/esophageal/renal disease. 
 
Approximately 512 patients need to be enrolled in the study to achieve the desired precision. Patient pool 
will be the orthopaedic clinic of Larisa Public Hospital. 
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4. STUDY OBJECTIVES 
 
Primary objective:  
Evaluate Bone Mineral Density (BMD) changes at lumbar spine of Greek osteoporotic women from baseline 
to 12th month from the initiation of Alendronate 70mg once weekly. 
 
Secondary objectives:  
Evaluate new vertebral and non-vertebral fragility fractures, hip fractures, treatment compliance, occurrence 
of back pain and days lost from work due to fracture related back pain from baseline to 12th month from the 
initiation of Alendronate 70mg once weekly. 
Also evaluate the safety of Alendronate assessed by the type, frequency, and severity of ADRs for 18 months 
after the initiation of study. 
 
 
 
5. BACKGROUND 
 
Disease 
Osteoporosis is described by the World Health Organization as a ‘progressive systemic skeletal disease 
characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent 
increase in bone fragility and susceptibility to fracture.1 Osteoporosis is a major public health threat; in a 
recent review, the prevalence of osteoporosis was reported as an estimated 200 million people worldwide 
while about 40 to 50% of women are at risk of having an osteoporotic fracture in their lifetimes.2,3 
Nonetheless, most women with osteoporosis remain asymptomatic, which makes epidemiological research 
especially difficult.4 Osteoporosis related fractures are associated with significant morbidity and mortality. 
Their non-fatal consequences include pain, physical impairment and loss of functional ability, which can have 
significant adverse effects on patient quality of life. There are also substantial costs to society in terms of 
diminished activity, hospitalization and lengthy stays in nursing homes as well as days lost from work.5 
A diagnosis of osteoporosis can be made on the base of either fractures occurring without significant trauma 
or low bone mineral density measured by dual energy X-ray absorptiometry (DXA).6 
According to the WHO diagnostic classification, osteoporosis in Caucasian women is defined as a bone 
mineral density (BMD) at the hip or lumbar spine that lies 2.5 standard deviations or more below the average 
for the young healthy female population (T-score <-2.5 S.D.).6 Osteoporosis can be treated effectively mainly 
by antiresorptive agents, such as bisphosphonates, by anabolic agents, such as parathyroid hormone 
analogues, by denosumab which is a fully human monoclonal antibody that inhibits RANKL, by strontium, and 
by raloxifen a selective estrogen receptor modulator.7,8 Other non-pharmacological strategies suggested 
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to reduce the burden of osteoporosis are smoking cessation and exercise.9 Bisphosphonates represent a 
major advance in osteoporosis treatment and remain at the forefront of medications used for years with 
great efficacy and safety for the care of patients.10 
 
Drug background  
Alendronate is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone 
formation. Preclinical studies have shown preferential localization of Alendronate to sites of active 
resorption. Activity of osteoclasts is inhibited, but recruitment or attachment of osteoclasts is not affected. 
The bone formed during treatment with Alendronate is of normal quality.11 
Alendronate is approved for the prevention (5 mg daily and 35 mg weekly tablets) and treatment (10 mg 
daily tablet, 70 mg weekly tablet) of postmenopausal osteoporosis. Alendronate is also approved for 
treatment to increase bone mass in men with osteoporosis and for the treatment of osteoporosis in men and 
women taking glucocorticoids.1 In the initial efficacy studies of Alendronate, the mean bone mineral 
density (BMD) increases with Alendronate 10 mg/day relative to placebo at three years with 8.8%, 5.9% 
and 7.8% at the spine, femoral neck and trochanter, respectively. Total body BMD also increased 
significantly. Also, Alendronate reduces the incidence of spine and hip fractures by about 50 percent over 
three years in patients with a prior vertebral fracture or in patients who have osteoporosis at the hip site. It 
reduces the incidence of vertebral fractures by 48 percent over three years in patients without a prior 
vertebral fracture. 12 
 
Rationale 
Even though regulatory approval has been granted for Alendronate many years ago, no large observational 
study has been conducted in Greek population to collect information on patient characteristics including 
demographics, comorbid conditions and use of concomitant medications and thus ensure that the drug is 
being used in patients that it was intended to. Moreover, findings of such a study will help describe women 
receiving Alendronate for osteoporosis in Greece highlighting at the same time the factors determining 
therapeutic choice and the patient’s fracture risk; comorbid conditions influencing bone health (including 
systemic, metabolic, rheumatic, thyroid, parathyroid, renal and lung); clinical factors related to osteoporosis 
(prior fracture, age, ambulatory status, bone turnover markers, BMD T-score, body mass index, Ca (calcium) 
and vitamin D intake; lifestyle factors (smoking, alcohol and drug use/abuse); and socioeconomic status 
(employed, retired). In addition, Alendronate efficacy will be confirmed in Greek population.  
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6. STUDY DESIGN 
 
This is a Greek observational prospective study to evaluate the effect of a biphosphonate drug, Alendronate, 
on BMD in postmenopausal women for a total period of 12 months. This observational study will not alter 
the routine clinical management of patients and will comply with all applicable local regulations of Greece. 
The decision to treat the patient with Alendronate must be made independent of and prior to their 
enrollment in the study. It is expected that patients eligible to participate will receive their first prescription 
during their initial clinic appointment and thereafter once monthly along with local standard clinical care 
according to clinical judgment and international guidelines. Approximately 512 patients will be enrolled in 
the study. The first 512 patients that will attend the orthopaedic clinic of Larisa Public Hospital and will be 
deemed appropriate candidates for biphosphonates treatment will be eligible to participate in the study. 
Detailed data obtained as part of routine clinical practice will be collected at the initial visit directly from 
patients or through their past medical record. These will comprise of demographic patient data, medical 
condition, risk factors for osteoporosis, and comorbidities. It is anticipated that patients will return to the 
clinic every month to receive their Alendronate prescription and record protocol adherence. After the initial 
visit, information regarding Alendronate prescription and administration, concomitant medication use, and 
non-serious and serious ADRs will be obtained during monthly clinical visits and recorded for up to 
approximately 6 months after completion of the study, a period that is thought appropriate to document 
ADRs and serious ADRs. 
 
 
 
7. SELECTION AND ENROLLMENT OF SUBJECTS 
 
Inclusion criteria:  
- Postmenopausal women who are diagnosed with osteoporosis either by a DXA scan 
with a T score <-2.5 either by suffering a low intensity fracture (even in the absence of 
a DXA scan with T score <-2.5). The bone location that will be used in this study – 
lumbar spine- is among the recommended for evaluation of BMD by bone 
densitometry. 
- Written informed consent 
 
Exclusion criteria: 
                                 -      Previous treatment with drugs that modify bone metabolism 
- Renal failure (GFR <35 ml/min, as suggested by drug spc) 
- History of reflux esophagitis, gastric or duodenal ulcers, gastrectomy 
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- Bone disease such as primary hyperparathyroidism, hyperthyroidism, Paget disease, 
Cushing syndrome, multiple myeloma, rheumatoid arthritis, or osteogenesis 
imperfecta. 
 
Enrollment:  
Patient pool will comprise of all patients attending the orthopaedic clinic of Larisa Public Hospital. The first 
512 patients assessed in this clinic and recommended based on national guidelines and international good 
clinical practice that they need to be treated with biphosphonates, will be candidates to be enrolled in this 
study. All patients must sign the appropriate consent form before being enrolled into the study. 
 
 
 
8. TREATMENT PROCEDURES AND STUDY PROCEDURES 
  
This study is designed to follow and observe patients who will initiate treatment with Alendronate 70mg in 
routine clinical practice. No study-specific treatment will be provided and no additional clinical procedures or 
assessments will be required as part of this observational study. Patients will be observed for a period of up 
to 12 months after their entry in the study unless patients discontinue the study or are lost to follow up. 
Information regarding the clinical management of the patients receiving Alendronate 70mg may be collected 
whenever available, even after treatment discontinuation.  
 
There are no procedures or changes to routine clinical management of patients. It is anticipated that patients 
will return to the clinic every month to receive their Alendronate 70mg prescription. Patients will be followed 
for approximately 6 months after their last visit. Available clinical information obtained for routine clinical 
practice (including those already recorded on the patient medical records ie, baseline characteristics) will be 
recorded, including Alendronate 70mg administration, previous and current therapies, medical history 
(including fracture history), ADRs and serious ADRs and co-morbidities. 
 
Throughout the study, investigators may prescribe any concomitant medications or treatments deemed 
necessary to provide adequate routine clinical care including calcium and vitamin D supplementation, which 
will be recorded. 
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9. REMOVAL AND REPLACEMENT OF PATIENTS  
 
Removal of Patients:  
Patients have the right to withdraw fully from the study at any time and for any reason without prejudice to 
her future medical care by the physician or at the institution. Withdrawal of full consent for this study means 
that the patient does not wish to or is unable to continue further study participation; patient data up to 
withdrawal of consent will be included in the analysis of the study. The investigator will discuss with the 
patient appropriate procedures for withdrawal from the study. Should a patient (or a legally acceptable 
representative) request or decide to withdraw from the study, all efforts will be made to complete and 
report the observations as thoroughly as possible up to the date of withdrawal. All information should be 
reported on the applicable eCRFs. 
 
Replacement of Patients:  
Participants who withdraw from the study or lost to follow-up will not be replaced. 
 
 
 
10. STATISTICAL CONSIDERATIONS 
 
Study Outcomes:  
The following outcomes are to characterize/estimate the effectiveness during the first 12 months of 
treatment with Alendronate.  
 
Primary outcome: 
- BMD change (%) at lumbar spine at 6,12 months of treatment measured by DXA  
 
Secondary outcomes: 
- the proportion of patients with severe osteoporosis experiencing one or more new vertebral and 
non-vertebral fragility fractures assessed by spine radiographs regardless of symptoms 
- Compliance to therapy, self-reported by patients 
- Days lost from work due to fracture-related back pain, self reported by patients 
 
The following secondary outcomes are to characterize the safety of patients during the first 12 months of 
treatment with Αlendronate and during the 6 month follow up period: 
- the proportion of patients with ADR to Alendronate 
- the proportion of patients with serious ADR to Alendronate 
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The Full Analysis Set will consist of all enrolled patients satisfying the inclusion/exclusion criteria that receive 
at least 46 doses - 96% of the 48 that ideally would receive during the study duration- and have a non-
missing enrollment date. All analyses will be performed on this analysis set. 
 
Subsets and/or Covariates: 
The following variables will be collected at baseline, either directly as part of routine clinical practice, or from 
medical records when available: 
Demographic patient data: 
 Educational level 
 Patient employment status 
 Patient living situation (at home with spouse/family, at home with care/support, at home alone, 
nursing home) 
Medical condition regarding osteoporosis: 
• Body mass index (≤ 25 or > 25 kg/m2) 
• Age at menopause  
• Cause of menopause (natural onset, clinically/surgically induced) 
• Height loss since maximal height  
• Height loss in centimeters (cm) 
• Previous fracture  
- Previous hip fracture  
- Previous vertebral fracture  
- Other previous fractures  
• Previous hospitalization for osteoporotic fracture and/or surgical osteoporotic fracture treatment  
• One or more falls experienced during the past 12 months  
• One or more episodes of immobility experienced during the past 12 months  
• Parent fractured hip  
• Current smoker  
• Former smoker  
• Systemic glucocorticoid use  
• Secondary osteoporosis  
• Alcohol consumption 
• Femoral neck BMD T-score 
• Lumbar spine BMD T-score 
• Total hip BMD T-score 
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Patient-related: 
• Age (years) 
• Age group (< 65, ≥ 65 to <75, ≥ 75 years) 
• Time since Post Menopausal Osteoporosis (PMO) diagnosis 
• Number of comorbidities 
• Any chronic medical condition 
• Type of chronic medical condition (diabetes/osteoporosis/hypertension/other) 
 
Sample Size: 
A review of published data highlighted that BMD change at lumbar spine at 12 months for postmenopausal 
women on alendronate 70mg weekly ranges from 3.7%-5.1%.13-15 
Taking into account the most unfavourable result, which is 5.1%, we will estimate the sample size of our 
study. We will conduct an observational study which intends to investigate the Lumbar Spine BMD (%) 
change from baseline to 12 months (single proportion). 
Published data estimate that Lumbar Spine BMD increases 5.1% from baseline to 12 months. 
We would like to ensure that 95% CI of the Lumbar Spine BMD change (%) is estimated with precision ±2% 
(i.e. with a margin of error of 2%). 
 
The required sample size would be n≥ 
  
  
 p(1-p) → n≥ 
     
     
 0.051(1-0.051) → n≥ 465 
If we add 10% to compensate for potential loss of subjects, the final number will sum up to n≥ 512 patients. 
 
Thus in order to have sufficient precision and compensate for potential loss of subjects the final sample size 
should be 512 patients. 
 
Data Analyses 
This is an observational study for which the analysis will be descriptive in nature and no formal hypothesis 
will be tested. T test will be used to assess the change in BMD between baseline and end of study 
measurements. Significance was indicated at P < 0.05.  
For quantitative parameters (BMD, days lost from work) mean, standard deviation, median, range (minimum 
and maximum), as well as number of missing data (if relevant) will be displayed. For qualitative parameters 
(bone fractures) counts, percentages and number of missing data if relevant will be displayed. Treatment 
compliance for each patient will be calculated as the number of doses study drug was actually taken, with 
the maximum count being 48. Compliance will be regarded as a quantitative parameter. 
In general, missing values will remain as missing, i.e., no attempt will be made to impute missing values and 
only observed values will be used in data analyses and presentations. 
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Baseline characteristics will be described. Demographics, medical history and other baseline variables will be 
summarized as appropriate to the type of data. 
 
 
 
11. SAFETY DATA SELECTION AND ADVERSE EXPERIENCE REPORTING 
 
Adverse Drug Reaction 
Definition of Adverse Drug Reaction: An Adverse Drug Reaction (ADR) is defined as an adverse event 
associated with a given medication at normal dosage. The definition of adverse events includes worsening of 
a pre-existing medical condition. Worsening indicates the pre-existing medical condition (eg, diabetes, 
migraine headaches, gout) has increased in severity, frequency, and/or duration, and/or has an association 
with a significantly worse outcome. A pre-existing condition that has not worsened during the study, and 
involves an intervention such as elective cosmetic surgery or a medical procedure while on study is not 
considered an adverse event. The Investigator should specify the date of onset, intensity, action taken with 
respect to Alendronate, corrective treatment/therapy given, outcome and his/her opinion as to whether 
there is a reasonable possibility that the Adverse Event was caused by Alendronate. 
 
Lab, vital signs, or ECG abnormalities are to be recorded as adverse events only if they are medically relevant: 
symptomatic, require corrective treatment, lead to study drug discontinuation and/or fulfill a seriousness 
criterion. In that case the procedure imposed by the event of a serious adverse drug reaction (SADR) should 
be followed. 
 
Reporting Procedures for Adverse Drug Reactions: The investigator is responsible for ensuring that all ADRs 
to Alendronate 70mg observed by the investigator or reported by the patient that occur after the first 
administration of Alendronate through the end of study and through the following 6 months are captured. 
The investigator must assess whether any adverse event is possibly related to Alendronate 70mg and if that 
is the case he should proceed by recording the ADR and assign the following ADR attributes: 
• ADR diagnosis or syndrome(s), if known (if not known, signs or symptoms), 
• Date(s) of onset and resolution, 
• Severity, and 
• Action taken. 
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Serious Adverse Drug Reaction 
Definition of Serious Adverse Drug Reaction: A SADR is a serious adverse event that is considered related to 
the medicinal product. A serious adverse event is defined as an adverse event that meets at least 1 of the 
following serious criteria: 
• fatal 
• life threatening (places the patient at immediate risk of death) 
• requires in-patient hospitalization or prolongation of existing hospitalization 
• results in persistent or significant disability/incapacity 
• congenital anomaly/birth defect 
• other medically important serious event 
An adverse event would meet the criterion of “requires hospitalization”, if the event necessitated an 
admission to a health care facility (eg, overnight stay). If an investigator considers an event to be clinically 
important, but it does not meet any of the serious criteria, the event could be classified as a serious adverse 
event under the criterion of “other medically important serious event”. Examples of such events could 
include allergic bronchospasm, convulsions, blood dyscrasias, drug-induced liver injury, or events that 
necessitate an emergency room visit, outpatient surgery, or urgent intervention.  
 
Reporting Procedures for Serious Adverse Drug Reaction: The investigator is responsible for ensuring that all 
SADRs related to Alendronate 70mg from the beginning of the study until the end of it and during the 6 
month follow up period are recorded in the patient’s medical record and are reported to a SADR report form. 
Information provided on the SADR form must be consistent with that recorded on the applicable eCRF (eg, 
Adverse Drug Reaction Summary eCRF). SADRs will be reported as required to National Organization for 
Medicines (EOF), in compliance with all reporting requirements according to local regulations for 
observational studies. 
 
 
 
12. REGULATORY OBLIGATIONS 
 
Informed consent:  
The Investigator (according to applicable regulatory requirements), or a person designated by the 
Investigator, and under the Investigator's responsibility, should fully inform the patient of all pertinent 
aspects of the clinical trial, including the written information given approval/favorable opinion by the 
Institutional Review Board/Ethics Committee of both the hospital where the study will take place and the 
Ethical Committee (EC) of the Ministry of Health of Greece. Prior to a patient’s participation in the study, the 
written Informed Consent Form should be signed, name filled in and personally dated by the patient or by 
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the patient’s legally acceptable representative, and by the person who conducted the informed consent 
discussion. A copy of the signed and dated written Informed Consent Form will be provided to the patient. 
 
Institutional Review Board/Independent Ethics Committee (IRB/EC):  
The Investigator must submit this Study Protocol to the appropriate IRB/EC, and is required to forward to the 
Sponsor a copy of the written and dated approval/favorable opinion signed by the Chairman with IRB/EC 
composition. The study number, study Protocol title and version number, the documents reviewed (study 
Protocol, Informed Consent Form, Investigator’s Brochure, Investigator’s CV, etc.) and the date of the review 
should be clearly stated on the written IRB/EC approval/favorable opinion. The investigator should notify the 
IEC/IRB of deviations from the protocol or serious adverse events occurring at the site and other adverse 
event reports recorded. 
All updates to the Investigator’s Brochure will be sent to the IRB/EC. If requested, a progress report will be 
sent to the IRB/EC 6 months after the initiation of the study and a summary of the study’s outcome at the 
end and after the 6 month follow up period of the study.  
 
Patient Confidentiality: 
All laboratory specimens, evaluation forms, reports, video recordings, and other records that leave the site 
will be identified only by the Study Identification Number (SID) to maintain patient confidentiality. All records 
will be kept in a locked file cabinet. All computer entry and networking programs will be done using SIDs 
only. Clinical information will not be released without written permission of the patient, except as necessary 
for monitoring by IRB. 
 
 
 
13. ADMINISTRATIVE AND LEGAL OBLIGATIONS 
 
The investigators are responsible for verifying the eCRFs at regular intervals throughout the study to verify 
adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local 
regulations on the conduct of observational studies. All investigators will have access to patient medical 
records and other study-related records needed to verify the entries on the eCRFs where applicable per local 
governing law and/or regulations. 
The investigator is responsible to ensure that any problems detected in the course of these monitoring visits, 
including delays in completing eCRFs, are resolved. 
 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:11:38 EET - 137.108.70.7
16 
 
Publication policy: 
Presentation and/or publication of the results of the study, using checked and validated data in order to 
ensure the accuracy of the results is highly encouraged. All investigators must participate sufficiently and 
contribute in any parts of conception, design, data collection/analysis, drafting of article, critical review of 
the article to be qualified as authors. All authors should have a copy of the presentation/publication prior to 
its release and approve it.  
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14. SUPPLEMENTARY MATERIAL 
 
Data collected per visit 
 
                                                          Timing 
 
        Data collection     
Enrollment Observation 
period 
End of Study  
(12 months) 
Follow-up period  
      (6 months) 
Informed Consent X    
Demographics X    
Patient-related conditions X    
Medical History X    
Prior and Current Medication Use X X X  
Menopause History X    
Alendronate Prescription X X X  
Calcium and Vitamin D 
supplementation 
X X X  
ADR X X X X 
SADR X X X X 
Discontonuation and Reasons for 
Discontinuation 
X X X  
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